here is great interest in mild cognitive impairment (MCI) as an intermediate state between normal aging and dementia. In its broadest sense, the term MCI encompasses a number of causes of cognitive decline, each with their own symptomatic treatment (Table I) . This list is not exhaustive, but includes the most common causes of consultation in memory clinics for cognitive decline over age 50: MCI of dysthymic, vascular, and amnestic etiologies. 1 This article will focus on the pharmacotherapy of the amnestic type of MCI because of the associated high risk of conversion to Alzheimer's disease (AD) and the availability of randomized clinical trials (RCTs) studying the safety and efficacy of a number of medications, over periods ranging from 6 months to 4 years.
What is amnestic MCI?
Amnestic MCI was defined by Petersen et al 2 in the context of a natural observation study, which demonstrated a rate of conversion to AD that was well above the incidence of age-matched populations. The original amnestic MCI criteria are as follows 2 : • Memory complaint, preferably corroborated by an informant.
• Memory impairment relative to age-and educationmatched normal subjects.
• Relatively normal general cognitive function.
• Largely intact activities of daily living (ADL).
• Not demented. A more recent subclassification of MCI has been proposed by Petersen 3 on the basis of findings from cognitive testing in larger number of subjects:
• Amnestic or single-memory MCI.
• Multiple-domain MCI.
• Single non-memory-domain MCI. same risk of conversion to AD, whereas the third group (single non-memory-domain MCI) may be a prodrome to the nonAD dementias. For the purpose of RCTs, operational criteria with specific inclusion/exclusion criteria have been specified.The criteria for the study completed by the Alzheimer Disease
Cooperative Study comparing donepezil with tocopherol and placebo 4 are listed in Table II ; this study will be referred to in this monograph as the Memory Impairment Study (MIS). Although not fully analyzed and published, entry criteria for the twin studies (with and without magnetic resonance imaging [MRI]) comparing galantamine and placebo are available 5 and are summarized in Table  III . The Investigation into the Delay to Diagnosis of AD with Exelon (rivastigmine) (InDDEx) study is not yet completed, but the entry criteria of this 4-year RCT comparing rivastigmine with placebo have been published. 6 These are listed in Table IV for purposes of comparison between the MIS, the galantamine studies, and the InDDEx study.
Hypothesis leading to RCTs for amnestic MCI
The fact that most patients with amnestic MCI convert to AD led to the hypothesis that they were suffering from a reduction in cholinergic activity, which is the basis for the so-called "cholinergic hypothesis of AD," at least in terms of its mainline symptomatic therapy. On the other hand, observations made by DeKosky et al 7 of increased choline acetyltransferase activity in the superior frontal cortex and hippocampus of subjects with MCI compared with controls and with subjects with mild AD suggested that a cholinergic deficit in amnestic MCI may not be as prominent as was initially postulated. The safety and efficacy of the acetylcholinesterase inhibitors (AChEIs) donepezil, galantamine, and rivastigmine have been studied extensively versus placebo in amnestic MCI . To date, results are available from a short-term (6-month) symp- tomatic study with donepezil and long-term studies with galantamine and donepezil. Etiological approaches to AD include anti-inflammatory drugs and it was logical to test cyclooxygenase-2 (COX-2)-selective inhibitors, such as refecoxib. Unfortunately, there have only been negative results reported from such studies and so these agents will not be discussed further in this monograph. Non-transmitter-specific drugs, such as piracetam, have also been tested, with negative results and will not be discussed further.
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Trial designs and outcomes to test symptomatic benefit in amnestic MCI
There has been much interest in the short-term benefit of drugs in amnestic MCI, with particular attention to cognitive outcomes. A 6-month study comparing donepezil with placebo was performed using parallel groups, with the Alzheimer's Disease Assessment 
Trial design and outcomes to test delay in conversion from amnestic MCI to AD
The possibility of delaying conversion from amnestic MCI to AD has attracted a lot of interest since it offers good face validity. Designs have included parallel groups with conversion to AD as a primary end point. This conversion has been defined operationally in different ways, ranging from a clinical opinion to a change in the Clinical Dementia Rating (CDR) scale Global Score from 0.5 to 1. Conversion committees were asked to monitor conversions taking place in the different RCTs and to analyze the key factors leading to conversion. This information will be very useful to design future RCTs and also for practicing clinicians who want reassurance in the very early diagnosis of AD, when ADL changes are minimal. Secondary outcomes in these studies include a number of cognitive, ADL, and global outcomes.
Results of symptomatic studies
The 6-month donepezil RCT has shown a statistically significant but small improvement in ADAS-cog, driven by the ADAS-cog Immediate Word Recall test. In the fully evaluable population, scores on the NYU Paragraph Immediate and Delayed Recall tests as well as the Digit Span Backwards test were significantly better in the donepezil group. 9 The CGIC measured by the clinician failed to detect a difference, but the self-rated impression of change from the subjects (PGA) showed a highly statistically significant difference between donepezil and placebo. Side effects were predominantly gastrointestinal (diarrhea, nausea, and vomiting) and nocturnal (abnormal dreams) at a higher frequency than patients with AD at a similar dose of 10 mg at bedtime. 10 
Results of conversion studies
The 2-year galantamine studies showed no difference in the primary analysis of conversion from amnestic MCI to AD. 11 Analysis of secondary outcomes is under way, but it is apparent that a reduced rate of whole-brain atrophy has been found in patients treated with galantamine. 12 Baseline demographics of the 3-year MIS have been reported 4 and are listed in Table V . An annual conversion rate of the order of 13% was reached with this amnestic MCI population, which most investigators would consider as prodromal AD. 13 Results of the primary analysis of MIS have been presented at the 9th International Conference on Alzheimer's Disease and Related Disorders: there was no difference in the primary analysis of conversion from amnestic MCI to AD after 3 years.
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14 Analysis of secondary outcomes is under way, and it is already apparent that there is a statistically significant delay of conversion between subjects treated with donepezil and placebo at 6, 12, and 18 months into the study, with the conversion curves overlapping at 24, 30, and 36 months. Patients carrying the apolipoprotein E4 (APOE-4) mutation were at a much higher risk of converting to AD and had a statistically significant protective effect from conversion on treatment with donepezil from month 6 until month 36. The results of the 4-year rivastigmine study should be available early 2005. Tolerability of AChEI in long-term amnestic MCI appears to be similar to patients with AD in terms of a predominance of gastrointestinal transient side effects. Their incidence and severity are slightly higher than in AD and lead to a higher rate of discontinuation, particularly in the first year of treatment.
Lessons so far
Although not all the data are in and not all subanalyses on the available data have been performed, it is apparent that the AChEI class does not delay the conversion from amnestic MCI to AD beyond 18 months. This suggests that the AChEIs have a symptomatic and potentially clinically significant effect, but one that is transient. This is congruent with the AD2000 study, which demonstrated a sustained benefit of donepezil on cognition using the Mini-Mental-State Examination (MMSE) and an ADL measure over 2 years.
15
In terms of safety, the gastrointestinal side effects of AChEIs appear to be more prominent in MCI than in AD, and lower doses may be preferred in both RCTs and clinical practice. Earlier diagnosis of AD has been facilitated by research on amnestic MCI. More patients presenting because of memory complaints will get a full assessment, seeking reversible causes, concomitant disorders, and risk factors, all of which are amenable to treatment.AChEIs will be one option for treatment, most likely at lower doses than are usual in AD. This option should not be recommended at this stage of our knowledge, but should not be denied for people who ask for it. It is premature to recommend that subjects with amnestic MCI be screened for APOE-4 genotype and only those with the APOE-4 mutation be treated, but genotyping must be done at entry into RCTs for MCI because of its strong effect on conversion rate; in other words, we must stratify for APOE-4 alleles between treatment arms.
The future
It is still early days in the analysis of what has been achieved with AChEIs and noncholinergic drugs in amnestic MCI. Already, RCT protocols are being created for other classes of drugs with (i) potential cognitive effects demonstrable in short-term 6-month studies; and (ii) potential effects delaying conversion to AD over 3 years. Placebo-controlled studies are not an issue in amnestic MCI, in contrast to mild-to-moderate AD.The prodromal stage of AD may be the most promising stage to test the efficacy and safety of disease-modifying drugs, when the neurons are still salvageable. ❏ P h a r m a c o l o g i c a l a s p e c t s 
